Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa. (12th November 2018)

• Record Type: Journal Article
• Authors: Edgeworth, Jonathan D; Merante, Domenico; Patel, Sanjay; Young, Christopher; Jones, Paul; Vithlani, Seema; Wyncoll, Duncan; Roberts, Peter; Jones, Andrew; Den Nagata, Tsutae; Ariyasu, Mari; Livermore, David M; Beale, Richard
• Is Part Of: Clinical infectious diseases. Volume 68:Number 11(2019)
• Page Start: 1932
• Page End: 1934
• Publication Date: 2018-11-12
• Subjects: cefiderocol -- endocarditis -- Pseudomonas aeruginosa -- drug resistance -- microbial; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciy963
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Serious infections such as endocarditis due to extremely drug-resistance gram-negative bacteria are an increasing challenge. Here, we present successful adjunctive use of cefiderocol for a patient with persistently bacteremic healthcare-associated native aortic valve endocarditis due to an extended-spectrum beta-lactamase–positive Pseudomonas aeruginosa susceptible in vitro only to colistin, following failure of conventional therapeutic options.